UE2343: Clinical Trials

4 trials of UE2343, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting. 4 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Active not recruiting 1
Phase 11Completed 1
Phase 31Active not recruiting 1

Follow UE2343: new trials by email Literature Review of UE2343 trials Research Report on UE2343

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem, Placebo - Dementia Moderate, Dementia, Mild
Phase 2 / Phase 3Active not recruitingActinogen Medical2472024-04-122026-10-21
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
Xanamem™, Placebo - Major Depressive Disorder, MDD
Phase 2CompletedActinogen Medical1672022-11-282025-01-22
A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers
Xanamem® 5 mg, Placebo, Xanamem® 10 mg - Mild Cognitive Impairment, Alzheimer's Disease
Phase 1 / Phase 2CompletedActinogen Medical1072021-06-302025-01-23
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
Xanamem™, Placebo (for Xanamem™) - Dementia, Alzheimer Type
Phase 2CompletedActinogen Medical1852017-03-232025-02-03

Conditions studied

Cognitive Dysfunction (3)  ·  Alzheimer Disease (2)  ·  Dementia (2)  ·  Depressive Disorder, Major (1)  ·  Lymphoma, Follicular (1)

Sponsors

Actinogen Medical (4)

Countries

Australia (4)  ·  United Kingdom (2)  ·  United States (2)

Top investigators

Alan Boyd, MD, FFPM (1)  ·  Bill Ketelbey, MD (1)  ·  Miriam Roesner (1)

Results publications

PMID 38848180